Uğur SELEK, Duygu SEZEN, Yasemin BÖLÜKBAŞI, Yücel SAĞLAM, Vildan ALPAN

VMAT vs Eight Field Imrt: Dosimetric Comparison of Pelvic Radiotherapy for Patients with High-Risk Prostate Cancer in Terms of Bone Marrow Sparing

Although there is no complete consensus on elective pelvic nodal irradiation for patients with high-riskprostate cancer, pelvic radiotherapy with androgen ablation has been more commonly used in many centers.An important part of bone marrow (BM) reserve remains in the pelvic radiation treatment field. This studyaimed to evaluate and compare the intensity modulated (step-and-shoot IMRT: ssIMRT) and volumetricmodulated arc radiotherapy (VMAT) techniques for pelvic radiotherapy in terms of pelvic BM doses.METHODSThis study was based on the simulation scan data of 10 patients with prostate cancer as 3-mm slicethickness using a full bladder and rectal balloon. The first phase of the treatment planning prescribed topelvic lymphatic (46 Gy/2 Gy/fraction). The second phase consisted of the seminal vesicles and prostate(32 Gy/2 Gy/fraction). The PTV margin was 0.4 cm posteriorly due to rectum and 0.6 cm in all other(including PTVlymphatic) directions. Using same target volumes, ssIMRT with eight angles (225°, 260°,295°, 330°, 30°, 65°, 100°, 135°) and double arc (182°, -178° arc angle) VMAT were planned for eachpatient data set. The planning objective was to cover the PTV by at least 95% of the prescribed isodoseand CTV by 98% of the prescribed isodose line. No special dose constraint was given for BM sparing.Each technique was compared by using dose volume histograms (DVH) of V5, V10, V20, V30, V40of the sacral BM (SBM), iliac BM (IBM), and ischium, pubis, and proximal femora (lower pelvis) andfemoral BM (FBM). In addition, V20 V30, V40, and V70 for bladder, and V30, V40, V76, and V80 forthe rectum, homogeneity index and the monitor units (MU) were evaluated. The two-sided Wilcoxon’stest was used for statistical analysis (p

PDF

___

1. Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, et al. Phase III trial comparing whole- pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: RadiationTherapy Oncology Group 9413. J Clin Oncol 2003;21(10):1904–11.
2. Lawton CA, DeSilvio M, Roach M 3rd, Uhl V, Kirsch R, Seider M, et al. An update of the phase III trial comparing whole pelvic to prostate onlyradiotherapy and neoadjuvant to adjuvant total androgen suppression: updatedanalysis of RTOG 94-13, with emphasis on unexpected hormone/radiationinteractions. Int J Radiat Oncol Biol Phys 2007;69(3):646–55.
3. Millar J, Boyd R, Sutherland J. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions: in regard to Lawton et al. (Int J Radiat Oncol Biol Phys 2007;69:646-655.). Int J Radiat Oncol Biol Phys 2008;71(1):316; author reply 316.
4. Pommier P, Chabaud S, Lagrange JL, Richaud P, Lesaunier F, Le Prise E, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007;25(34):5366–73.
5. Mauch P, Constine L, Greenberger J, Knospe W, Sullivan J, Liesveld JL, et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys 1995;31(5):1319–39.
6. Mundt AJ, Lujan AE, Rotmensch J, Waggoner SE, Yamada SD, Fleming G, et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002;52(5):1330–7.
7. Mell LK, Tiryaki H, Ahn KH, Mundt AJ, Roeske JC, Aydogan B. Dosimetric comparison of bone marrowsparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys 2008;71(5):1504–10.
8. Albuquerque K, Giangreco D, Morrison C, Siddiqui M, Sinacore J, Potkul R, et al. Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT. Int J Radiat Oncol Biol Phys 2011;79(4):1043–7.
9. Liang Y, Bydder M, Yashar CM, Rose BS, Cornell M, Hoh CK, et al. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies. Int J Radiat Oncol Biol Phys 2013;85(2):406–14.
10.Sini C, Fiorino C, Perna L, Noris Chiorda B, Deantoni CL, Bianchi M, et al. Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation. Radiother Oncol 2016;118(1):79–84.
11.Morikawa LK, Roach M 3rd. Pelvic nodal radiotherapy in patients with unfavorable intermediate and highrisk prostate cancer: evidence, rationale, and future directions. Int J Radiat Oncol Biol Phys 2011;80(1):6–16.
12.Myrehaug S, Chan G, Craig T, Weinberg V, Cheng C, Roach M 3rd, et al. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2012;82(4):e657–62.
13.Kopp RW, Duff M, Catalfamo F, Shah D, Rajecki M, Ahmad K. VMAT vs. 7-field-IMRT: assessing the dosimetric parameters of prostate cancer treatment with a 292-patient sample. Med Dosim 2011;36(4):365–72.
14.Davidson MT, Blake SJ, Batchelar DL, Cheung P, Mah K. Assessing the role of volumetric modulated arc therapy (VMAT) relative to IMRT and helical tomotherapy in the management of localized, locally advanced, and post-operative prostate cancer. Int J Radiat Oncol Biol Phys 2011;80(5):1550–8.
15.Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, et al. RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009;74(2):383–7.
16.Quan EM, Li X, Li Y, Wang X, Kudchadker RJ, Johnson JL, et al. A comprehensive comparison of IMRT and VMAT plan quality for prostate cancer treatment. Int J Radiat Oncol Biol Phys 2012;83(4):1169–78.
17.Wolff D, Stieler F, Welzel G, Lorenz F, Abo-Madyan Y, Mai S, et al. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol 2009;93(2):226–33.
18.Bedford JL. Treatment planning for volumetric modulated arc therapy. Med Phys 2009;36(11):5128–38.
19.Boylan CJ, Golby C, Rowbottom CG. A VMAT planning solution for prostate patients using a commercial treatment planning system. Phys Med Biol 2010;55(14):N395–404.
20.Kinhikar RA, Pawar AB, Mahantshetty U, Murthy V, Dheshpande DD, Shrivastava SK. Rapid Arc, helical tomotherapy, sliding window intensity modulated radiotherapy and three dimensional conformal radiation for localized prostate cancer: a dosimetric comparison. J Cancer Res Ther 2014;10(3):575–82.
21.Yoo S, Wu QJ, Lee WR, Yin FF. Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes. Int J Radiat Oncol Biol Phys 2010;76(3):935–42.
22.Khan MI, Jiang R, Kiciak A, Ur Rehman J, Afzal M, Chow JC. Dosimetric and radiobiological characterizations of prostate intensity-modulated radiotherapy and volumetric-modulated arc therapy: A single-institution review of ninety cases. J Med Phys 2016;41(3):162–8.
23.Ren W, Sun C, Lu N, Xu Y, Han F, Liu YP, et al. Dosimetric comparison of intensity-modulated radiotherapy and volumetric-modulated arc radiotherapy in patients with prostate cancer: a meta-analysis. J Appl Clin Med Phys 2016;17(6):254–62.
24.Lujan AE, Mundt AJ, Yamada SD, Rotmensch J, Roeske JC. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2003;57(2):516–21.
25.Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008;70(5):1431–7.
26.Schneider U, Sumila M, Robotka J, Gruber G, Mack A, Besserer J. Dose-response relationship for breast cancer induction at radiotherapy dose. Radiat Oncol 2011;6:67.
27.Travis LB, Andersson M, Gospodarowicz M, van Leeuwen FE, Bergfeldt K, Lynch CF, Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000;92(14):1165–71.
28.Vande Berg BC, Malghem J, Lecouvet FE, Maldague B. Magnetic resonance imaging of the normal bone marrow. Skeletal Radiol 1998;27(9):471–83.
29.Ai J, Xie T, Sun W, Liu Q. Red bone marrow dose calculations in radiotherapy of prostate cancer based on the updated VCH adult male phantom. Phys Med Biol 2014;59(7):1815–30.